Dr. Christine Rousseau became Chief Business Development Officer at the American Society for Microbiology (ASM) on December 1st, 2020. She has served as a bridge between public and private sectors while supporting the development of diagnostics, devices and vaccines. She has experience in strategy development, partnership engagement, clinical/regulatory affairs (Global Health, Infectious Disease, Cancer), and business management. At ASM, Christine leads the Global Public Health Program, Corporate Council, grants/donations and new business lines. In her former roles as a Vice President of Corporate Development at Chembio Diagnostics Systems, Inc. and as Senior Program Officer at the Bill & Melinda Gates foundation, she established partnerships between biopharmaceutical, diagnostic, academic and global organizations including Takeda, Mylan, Roche, UNICEF, UNITAID, the Global Fund and many others, directing over $250M USD in assets for the development of molecular, cellular, and serology diagnostic technologies. Her work included the creation of an African innovation hub to support laboratory systems globally and an African research organization to support regulatory studies. She played leadership roles on cross-functional teams covering corporate strategy, acquisition prospecting, deal negotiations and financial investments, i.e. grants, equity, loans, strategic partnerships, license agreements. Dr. Rousseau has been recognized for integrity, strategic acumen, leadership and scientific expertise.